A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)
Phase of Trial: Phase IV
Latest Information Update: 21 Apr 2017
Price : $35 *
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TOLERATE
- Sponsors Biogen
- 31 Aug 2018 Biomarkers information updated
- 17 Sep 2016 Safety results (n=212) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 09 Apr 2016 Status changed from recruiting to completed.